Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

MLA

Hamid, Omid, et al. “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.” The New England Journal of Medicine, vol. 369, no. 2, July 2013, pp. 134–44. EBSCOhost, https://doi.org/10.1056/NEJMoa1305133.

APA

Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., Dronca, R., Gangadhar, T. C., Patnaik, A., Zarour, H., Joshua, A. M., Gergich, K., Elassaiss-Schaap, J., Algazi, A., Mateus, C., … Ribas, A. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine, 369(2), 134–144. https://doi.org/10.1056/NEJMoa1305133

Chicago

Hamid, Omid, Caroline Robert, Adil Daud, F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D Wolchok, et al. 2013. “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.” The New England Journal of Medicine 369 (2): 134–44. doi:10.1056/NEJMoa1305133.